<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="426">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559169</url>
  </required_header>
  <id_info>
    <org_study_id>UHN-TWH-VER-001</org_study_id>
    <nct_id>NCT00559169</nct_id>
  </id_info>
  <brief_title>Verapamil and Catamenial Epilepsy</brief_title>
  <official_title>Study of Verapamil in Refractory Catamenial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related
      to the over expression of multidrug resistance proteins (MDR). Progesterone is a known
      inhibitor of MDRs and the low level of this hormone during the menstrual cycle may
      exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during
      the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by
      inhibiting MDRs and thus may help patients with refractory seizures. If the study shows
      improved seizure control, the results will help establish the role of MDRs in refractory
      epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    protocol changed and a new study using verapamil in epilepsy will be started in the near
    future
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the percent reduction in seizure frequency</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Catamenial Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verapamil hyrochloride</intervention_name>
    <description>80 mg daily by mouth, 5 days prior to menses for 3 months</description>
    <other_name>apo-verap, isoptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  females

          -  at least 2 seizures per month

          -  more than 50% of the seizures occur 7 days before or 7 days after the onset of menses

          -  patient of the Toronto Western Hospital Epilepsy Clinic

        Exclusion Criteria:

          -  cardiovascular history
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Andrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>College of Physicians and Surgeons of Ontario</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <lastchanged_date>April 7, 2010</lastchanged_date>
  <firstreceived_date>November 14, 2007</firstreceived_date>
  <keyword>epilepsy</keyword>
  <keyword>seizures</keyword>
  <keyword>menstrual cycle</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
